scholarly journals Improvement of Lipid Profile after One-Anastomosis Gastric Bypass Compared to Sleeve Gastrectomy

Nutrients ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 2770
Author(s):  
Silvia Bettini ◽  
Gianni Segato ◽  
Luca Prevedello ◽  
Roberto Fabris ◽  
Chiara Dal Prà ◽  
...  
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Lipid Profile ◽  
Severe Obesity ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
One Anastomosis Gastric Bypass ◽  
The Difference

Fewer studies compared the improvement of plasma lipid levels after different types of surgery, in particular compared to one-anastomosis gastric bypass (OAGB). The aim of our study was to investigate how laparoscopic sleeve gastrectomy (LSG) and OAGB impact on weight loss and lipid profile 18 months after surgery, in patients with severe obesity. Forty-six patients treated with OAGB were matched to eighty-eight patients submitted to LSG. Weight loss after OAGB (33.2%) was more evident than after LSG (29.6%) (p = 0.024). The difference in the prevalence of dyslipidemia showed a statistically significant reduction only after OAGB (61% versus 22%, p < 0.001). After adjustment for delta body mass index (BMI), age and sex, we demonstrated a statistically significant decrease of the differences between the changes before and after (delta Δ) the two surgery procedures: Δ total cholesterol values (p < 0.001), Δ low density lipoprotein-cholesterol values (p < 0.001) and Δ triglycerides values (p = 0.007). Patients with severe obesity undergoing to OAGB presented a better improvement of lipid plasma values than LSG patients. The reduction of lipid plasma levels was independent of the significant decrease of BMI after surgery, of age and of sex.

scholarly journals Is One Anastomosis Gastric Bypass with a Biliopancreatic Limb of 150 cm Effective in the Treatment of People with Severe Obesity with BMI > 50?

2021 ◽  
Author(s):  
Arnaud Liagre ◽  
Francesco Martini ◽  
Radwan Kassir ◽  
Gildas Juglard ◽  
Celine Hamid ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Gastric Bypass ◽  
Severe Obesity ◽  
Postoperative Mortality ◽  
One Anastomosis Gastric Bypass ◽  
Sustained Weight Loss ◽  
Biliopancreatic Limb ◽  
Percentage Excess Weight Loss

Abstract Purpose The treatment of people with severe obesity and BMI > 50 kg/m2 is challenging. The present study aims to evaluate the short and mid-term outcomes of one anastomosis gastric bypass (OAGB) with a biliopancreatic limb of 150 cm as a primary bariatric procedure to treat those people in a referral center for bariatric surgery. Material and Methods Data of patients who underwent OAGB for severe obesity with BMI > 50 kg/m2 between 2010 and 2017 were collected prospectively and analyzed retrospectively. Follow-up comprised clinical and biochemical assessment at 1, 3, 6, 12, 18, and 24 months postoperatively, and once a year thereafter. Results Overall, 245 patients underwent OAGB. Postoperative mortality was null, and early morbidity was observed in 14 (5.7%) patients. At 24 months, the percentage total weight loss (%TWL) was 43.2 ± 9, and percentage excess weight loss (%EWL) was 80 ± 15.7 (184 patients). At 60 months, %TWL was 41.9 ± 10.2, and %EWL was 78.1 ± 18.3 (79 patients). Conversion to Roux-en-Y gastric bypass was needed in three (1.2%) patients for reflux resistant to medical treatment. Six patients (2.4%) had reoperation for an internal hernia during follow-up. Anastomotic ulcers occurred in three (1.2%) patients. Only two patients (0.8%) underwent a second bariatric surgery for insufficient weight loss. Conclusion OAGB with a biliopancreatic limb of 150 cm is feasible and associated with sustained weight loss in the treatment of severe obesity with BMI > 50 kg/m2. Further randomized studies are needed to compare OAGB with other bariatric procedures in this setting. Graphical abstract

Short-Term Results of Single-Anastomosis Gastric Bypass After Failed Sleeve Gastrectomy

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Alaa Abbas Sabry ◽  
Karim Sabry Abd-Elsamee ◽  
Mohamed Ibrahim Mohamed ◽  
Mohammed Mohamed Ahmed Abd-Elsalam
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Weight Regain ◽  
Revisional Surgery ◽  
One Anastomosis Gastric Bypass ◽  
Short Term ◽  
Multicenter Studies ◽  
Metabolic Outcomes

Abstract Background It is already known that Laparoscopic sleeve gastrectomy (LSG) has gained popularity as a stand-alone procedure with good short-term results for weight loss. However, in the long-term, weight regain is considered as a complication. Demand for secondary surgery is rising, partly for this reason, but through that study we try to discover the efficacy of conversion of failed sleeve gastrectomy to one anastomosis gastric bypass (OAGB) regarding weight loss and metabolic outcomes. Objective To asses the efficacy and safety of one anastomosis gastric bypass (OAGB) as a conversion surgery post Sleeve Gastrectomy failure as regard weight loss and metabolic outcomes. Patients and Methods This study is a retrospective cohort study which included 20 patients underwent one anastomosis gastric bypass at Ain-Shams University El-Demerdash Hospital, Cairo, Egypt and specialized bariatric center, Cairo, Egypt From February 2019 to July 2019 with 6 months of postoperative follow up till January 2019. Results In this study, we reviewed and analyzed the outcomes from the revision of the SG due to either inadequate weight loss or weight regain to one anastomosis gastric bypass (OAGB) with %EBWL of 6.65% at 1 month, 13.61 % at 3 months and 20.86% at 6 months. Conclusion OAGB appears to be an effective and safe therapeutic technique as a revisional surgery for failed primary SG with good short-term results for treating morbid obesity and its associated comorbidities with a significantly low rate of complications. However the EBWL was less than what is reported after primary OAGB weight. Multicenter studies with larger series of patients and longer term follow up after SG revisions to OAGB are warranted.

scholarly journals Plasma lipid profile of mice fed diet supplemented with broiler fat

2014 ◽  
Vol 43 (1) ◽  
pp. 21-24 ◽  
Author(s):  
GB Das ◽  
ME Hossain ◽  
MA Akbar
Keyword(s):  
Lipid Profile ◽  
Palm Oil ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Dietary Treatment ◽  
Blood Lipid ◽  
Blood Cholesterol ◽  
Control Group ◽  
Blood Lipid Profile

This study was conducted with 180 female Swiss albino mice to examine the effects of supplementing broiler fat in the diets of mice on blood lipid profile. Twenty one days old mice were collected from ICDDRB, Mohakhali, Dhaka. They were randomly distributed in four groups having three replications each. Each replicate group had 15 mice. Results revealed that supplementation of broiler fat in mice diet significantly changed (p<0.05) triglyceride (TG) and low density lipoprotein (LDL) among groups. The control group (T0) had the highest level of cholesterol and LDL. Cholesterol, TG and LDL markedly increased (p<0.05) in all dietary treatment groups, while high density lipoprotein (HDL) significantly (p<0.01) decreased after supplementation of experimental diets. It was concluded that all the dietary treatments in general increased blood cholesterol, TG and LDL in mice fed broiler fat with different oil supplements. However, the soybean and palm oil group was comparatively better than other groups in respect of cholesterol, HDL and LDL at the blood lipid profile of mice. Therefore, it can be concluded that consumption of broiler fat with soybean and palm oil could be less harmful for mice.DOI: http://dx.doi.org/10.3329/bjas.v43i1.19380 Bang. J. Anim. Sci. 2014. 43 (1): 21-24

scholarly journals A sympathetic gut connection drives the metabolic benefits of Roux-en-Y gastric bypass

Cell Stress ◽  
2020 ◽  
Vol 4 (12) ◽  
pp. 265-269
Author(s):  
Mohammed K. Hankir
Keyword(s):  
Weight Loss ◽  
Gastric Bypass ◽  
Body Weight ◽  
Sleeve Gastrectomy ◽  
Severe Obesity ◽  
Resting Metabolic Rate ◽  
Splanchnic Nerve ◽  
Negative Energy ◽  
Recent Issue ◽  
White Fat

Surgery is regarded by many as the go-to treatment option for severe obesity; yet how physically altering the gastrointestinal tract produces such striking results on body weight and overall metabolic health is poorly understood. In a recent issue of Cell Reports Ye et al. (2020) compare mouse models of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), the two most commonly performed weight loss surgeries in the clinic today, to show that the former reconfiguring procedure selectively increases resting metabolic rate through splanchnic nerve-mediated browning of mesenteric white fat. More significantly, they demonstrate that this effect for RYGB is required for the maintained negative energy balance and improved glycemic control that it confers.

scholarly journals Role of Vernonia Amygdalina on Plasma Lipid Profile, Liver and Kidney Enzymes in Rats with Streptozotocin-Induced Diabetes

2020 ◽  
pp. 93-102
Author(s):  
Gabriel Olukayode Ajayi ◽  
Elvis Uchechukwu Obi ◽  
Elizabeth Namesegua Elegbeleye ◽  
Precious Titilayo Obayemi ◽  
Oyindamola Mary Edamisan
Keyword(s):  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Diabetic Rats ◽  
Lipoprotein Cholesterol ◽  
Vernonia Amygdalina ◽  
Liver And Kidney ◽  
Streptozotocin Induced Diabetes

Diabetes mellitus is a non-communicable disease which has been associated with liver and kidney injuries, and at the same time affects lipid profiles. The aim of this study was to investigate the role of Vernonia amygdalina (VAM) on plasma lipid profile, liver and kidney enzymes in rats with streptozotocin -induced diabetes. Twenty-five male albino wistar rats weighing between 137 and 223 g were randomly grouped into five of five rats per group as follows: control, diabetic, diabetic + metformin (MET), diabetic + VAM at 150, 300 mg/kg. Diabetes was induced by administration of 45 mg/kg body weight streptozotocin (STZ) dissolved in citrate buffer (0.01 M, pH 4.5) by single intraperitoneal injection. Three days after, when diabetes was confirmed, MET and VAM were administered daily by oral gavage for 7 days. Animals were fasted overnight after the last administration of MET and VAM, sacrificed, blood was collected and plasma prepared for lipid profile estimation. Liver and kidney were collected, weighed, homogenized and supernatants obtained for enzymes and biochemical assays. There were no significant (p>0.05) change in the weights of animal, liver and kidney, liver/rat and kidney/rat ratios, plasma cholesterol (CHOL) concentration, activities of liver and kidney aspartate aminotransferase (AST), alanine aminotransferase (ALT), liver gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), and liver and kidney total protein (TPRO) concentrations; significant (p<0.05) decrease in triglyceride (TRIG), high density lipoprotein-cholesterol (HDL), low density lipoprotein-cholesterol (LDL), very low density lipoprotein-cholesterol (VLDL); and significant (p<0.05) increase in fasting blood glucose (FBG) level, kidney GGT, LDH activities, liver and kidney creatinine (CREA) and total bilirubin (TBIL) concentrations of diabetic (STZ) rats compared with normal control. The treatment of the diabetic rats with MET and VAM significantly modulated positively these parameters compared with the diabetic rats. This study further explains the protective role played by VAM in dyslipidaemia, liver and kidney injuries resulting from diabetes.

Sign in / Sign up

Export Citation Format

Share Document